Metabasis Therapeutics, Inc.

Mingwei Chen

Scott J Hecker

Venkat Reddy Mali

Qun Dang

Serge H Boyer

Robert Huerta Lemus

Zhili Sun

Haiqing Li

Jorge E Gomez-Galeno

Thanh Huu Nguyen

Matthew P Grote

Paul D Van Poelje

William Craigo

Raja K Reddy

Mali Venkat Reddy

K Raja Reddy

Serge Henri Boyer

Paul D Van Polje

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.

Antagonists of the glucagon receptor

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Growing community of inventors

San Diego, CA, United States of America

Mingwei Chen